EP15A3 Based Precision and Trueness Verification of VITROS HbA1C Immunoassay
- 89 Downloads
Verification of analytical performance of measurands becomes an essential requirement for the laboratories before proceeding to patients’ samples testing. In our study we have verified the performance of HbA1C Immunoturbidimetric assay (VITROS 5600) against manufacturers’ claims using CLSI EP15A3 Guidelines. We performed our study using two concentrations of Quality Control from Bio-Rad (Level 1 and Level 2). A precision verification study was carried out using five replicates of QC per day for five days following which imprecision estimates in form of Within Run (Repeatability) %CV and Within Lab %CV were calculated and compared against manufacturer’s claims. Second part of our study included derivation of grand mean from the results of 25 replicates of QC used for precision verification. This was compared against the Target Value of the assigned QC obtained from the peer group mean of laboratories participating in interlaboratory QC program (unityTM Interlab-Bio-Rad) for %bias estimation. The findings of our precision study showed an acceptable Within Lab imprecision (%CVWL-0.6%), while the %CV -repeatability (%CVR-0.54%) was greater than the manufacturer’s claim (σR-0.5%). Hence upper verification limit for the manufacturer’s claim (0.65%) was calculated against which the %CV Repeatability was compared and was found to be acceptable. The trueness verification showed that our grand mean (5.488%) was within the verification interval of the target value (5.462–5.497%) and hence the actual %bias was not statistically significant. Our study demonstrates that HbA1C immunoassay shows an acceptable performance consistent with the manufacturer’s claims.
KeywordsVerification EP 15 A3 Precision Trueness HbA1c
International organisation for standardisation
Clinical laboratory standards institute
Co-efficient of variation
The authors acknowledge the support of management of Madras Institute of Traumatology (MIOT) Hospital for their encouragement and support in this work.
This study was not funded by any organization
Compliance with Ethical Standards
Conflict of interest
None of the authors of this study have any conflict of interest.
This article contains study only with quality control materials commercially obtained. No patient samples were involved.
- 2.International Standards Organisation. Medical laboratories—Requirements for quality and competence International Standard, ISO 15189, 3rd (ed) 2012.Google Scholar
- 3.Westgard JO. Basic method validation. 3rd ed. Madison: Westgard QC Inc; 2008. p. 58.Google Scholar
- 4.Clinical and Laboratory Standards Institute. User verification of precision and estimation of bias; approved guideline-3rd (ed) Wayne, PA, USA: CLSI; 2014. CLSI document EP15-A3.Google Scholar
- 5.Clinical and Laboratory Standards Institute. User verification of performance for precision and trueness; approved guideline-2nd (ed) Wayne, PA, USA: CLSI; 2005. CLSI document EP15-A2.Google Scholar
- 6.Standardisation of HbA1c. In: IFCC standardization oh HbA1c. National Glycohemoglobin standardization program.2010. http://www.ngsp.org/ifccngsp.asp.
- 7.lglewicz B, Hoaglin DC. 1944-How to Detect and Handle Outliers. ASQC Quality Press, Wis.:Milwaukee; 1993.Google Scholar
- 8.Barnett V, Lewis T. Outliers in Statistical Data. 3rd ed. Hoboken: John Wiley & Sons Ltd; 1994.Google Scholar
- 9.Ostertagova E, Ostertag O. Methodology and application of one-way ANOVA. AJME. 2013;1(7):256–61.Google Scholar
- 10.Evaluating Chesher D, Precision Assay. Clin Biochem Rev. 2008;29(1):S23–6.Google Scholar